Class II recall: Baxter Healthcare Corporation: Vasopressin, in 0.9% Sodium Chloride Injection, 20 units per 100 mL (0.2 units/m

The FDA has classified as a Class II recall Baxter Healthcare Corporation's Vasopressin, in 0.9% Sodium Chloride Injection, 20 units per 100 mL (0.2 units/mL), 100 mL Single-Dose Container (NDC 0338-9640-12). The recall notice cites cGMP deviations as the reason for the action. No further details on the specific deviation or clinical impact were provided in the source text.

Most relevant for: Patients receiving vasopressin for conditions such as variceal bleeding or cardiogenic shock in acute care settings

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.